Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia [review]

Burnett, Alan Kenneth and Kell, Jonathan 2000. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia [review]. Current Opinion in Oncology 12 (2) , pp. 110-115. 10.1097/00001622-200003000-00002

Full text not available from this repository.


Collaborative study groups have invested considerable effort in the last decade in defining the role of allogeneic and autologous bone marrow transplantation as consolidation treatment for first remission of acute myeloid leukemia in younger patients. These efforts have been able, more precisely, to quantitate the degree to which patients who receive transplantation are a selected group. There has been a trend in recent years to increase the intensity of chemotherapy, which has improved treatment results, and the factors which determine the risk of relapse have become more widely acknowledged. These developments have made the appropriate choice of consolidation treatment less clear. Transplantation significantly reduces the risk of relapse and in some trials has improved the disease-free survival. However, a clear benefit in overall survival has been less clear and more difficult to demonstrate, partly because some patients who fail first-line chemotherapy can be salvaged in second remission. The trials that included high-dose cytarabine (ara-C) in the chemotherapy schedule were the ones in which no survival benefit was seen.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RZ Other systems of medicine
Uncontrolled Keywords: Adolescent, Adult, Antimetabolites, Antineoplastic / administration&dosage*, Bone Marrow Transplantation*, Clinical Trials as Topic, Cytarabine / administration & dosage*, Disease-Free Survival, Female, Humans, Leukemia Myeloid Acute / therapy*, Male,Middle Aged, Prognosis Substances Antimetabolites, Antineoplastic Cytarabine
Additional Information: Full Text Sources Lippincott Williams & Wilkins Ovid Technologies, Inc. Other Literature Sources Labome Researcher Resource - ExactAntigen/Labome Medical Acute Myeloid Leukemia - MedlinePlus Health Information Bone Marrow Transplantation - MedlinePlus Health Information Molecular Biology Databases CYTARABINE - HSDB
Publisher: Lippincott, Williams & Wilkins
ISSN: 1040-8746
Last Modified: 25 Jun 2017 04:42

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item